Metabolomics Market

Market Overview

The global metabolomics market size was valued at USD 1674 million in 2019 and is expected to grow at a CAGR of 13.5% during the forecast period.

Metabolomics is a branch of omics sciences that deals with the study of biochemical processes, which involves the study of intermediates and byproducts of metabolic activities. These products from the metabolic pathways are called metabolomes, which includes the cluster of all metabolites involved in various body functions such as metabolic intermediates, signaling molecules, secondary metabolites, and hormones.

Scientifically, a metabolomic study involves various analytical techniques (spectroscopy, chromatography, and bioinformatics) and statistical tools (multivariate analysis for the determination and study of metabolites). The study of these metabolites can help in a wide range of applications, such as substantial equivalence testing, phenotyping of genetically modified plants, identification of gene function, and study of biotic-abiotic stress reaction.

Market Dynamics

The Potential of Metabolomic Techniques in Therapeutics to Boost the Market Growth

Over the last decade, metabolomics has gained great traction due to its capabilities in disease biology research. Many studies have revealed, the optimum level of specific metabolites can associate with the onset/progression of diseases. The metabolomic studies can be used to understand the response to treatment for such metabolite-related diseases.

With the rapidly-rising prevalence and associated fatality-chronic lifestyle diseases, such as cancer and CVDs, researchers take increased efforts to develop novel therapeutic approaches using metabolomic tools. Further, it is facilitating researchers and scientists to estimate physiological effects and monitor the adverse drug reactions. Thus, many pharmaceutical and biotech companies, research institutes have a huge capital for metabolomic researches.

As reported by The Metabolomics Innovation Centre (TMIC), metabolomics research has experienced tremendous growth during the past decade. Thus, this extensive usage has fueled the market to achieve steady growth during the forecast period.

Rising Awareness and Funding from Government and Private Authorities Fuel the Market Growth

The metabolomics market has wide-scale applications in numerous domains. The notable research improvements supported by the market products and tools have generated awareness and support from several governments and private funding authorities across the globe. Thus, the market is recently witnessing increased funding opportunities, which positively influences the market growth.

According to the National Institute of Health (NIH), in 2018, the U.S. had invested more than USD 65 million in the Regional Comprehensive Metabolomics Resource Cores. According to the Metabolomics Innovation Center, Strategy Plan 2019-2024, Canada had invested more than USD 30 million in advancing the research infrastructure and boosting metabolomic research.

In January 2021, the National Institute of Health (NIH) funded the University of Massachusetts with a four-year project with USD 1.37 million, to advance the analysis of data-driven metabolomics research. Thus, the increasing investment and support in metabolomics research fuels the adoption of market products and ultimately drives the market growth.

Regional Analysis

America Accounts for Majority Share of the Market

Based on the region, the American market dominated the global market in terms of revenue. Due to multiple factors, the market is anticipated to continue its dominance at a steady CAGR. The large share of the American region can attribute to the presence of significant players such as Agilent, Thermofisher, and others, established within the regional market providing a home-state advantage and geographic presence.

The rapidly growing regional standards of research in the biomedical and healthcare domain are continuously integrating advanced technologies and development into research that leads to extensive utilization of metabolomics tools and directly boosts the adoption of market products. Additionally, the region is packed with pharmaceutical and biotech companies such as Pfizer, Mylan, and others along with CROs that are participating in rising preclinical activities that involve usage of market products.

Asia-Pacific Market Anticipated to Record Highest Growth Rate

The Asia-Pacific market is expected to register the highest CAGR during the forecast period. The steady exponential growth rate is expected to be backed with the rising disease burden faced that immensely boosts the demand for therapeutic measures and accurate diagnostic techniques. Thus, the regional market is booming as these metabolomic tools are used to meet up the demands.

The Asia-Pacific regions comprise of mostly developing economies such as Japan, China, India, Korea, Australia that are constantly channeling efforts and funding research to develop sound and advanced healthcare facilities. The prevalence of chronic diseases such as cancer, CVDs, among others has been sky high, and more dedicated efforts are projected towards disease management.

According to the Cancer Atlas, in 2018, 8.2 million cancer cases were diagnosed which corresponds to 5.2 million deaths in the region. This corresponds to approximately 50% of the global cancer burden. It is reported that China alone accounted for around 52% of new cancer cases and 55% of fatal incidents due to cancer within the region.

The key players in the regional market are Agilent, Thermo Fischer, Danaher, Merck, and Cytiva that have businesses all across the region. Thus, market products are likely to be available easily.

Segmental Analysis

The Metabolomics Instrument Segment Accounts for the Largest Market Share

Based on products and services, the metabolomics instrument segment is expected to account for the largest market share. The market dominance is due to the technological advancements in analytical instruments, such as increased efficacy, process automation, and computerization coupled with extensive usage of market products in research activities globally, in the field of medicine, nutraceuticals, and metabolomics.

Mass spectroscopy and NMR spectroscopy that is frequently used for metabolome profiling, are now powered by technological tools such as Big Data, Artificial Intelligence ad Machine Learning features. Also, most developing nations are actively looking to strengthen the current healthcare infrastructure using metabolomic approaches to enable efficient disease diagnosis and treatment. Thus, propelling the segment growth segment during the forecast period.

Cancer Segment Expected to Record a Fastest Growth

Based on indication, the cancer segment is expected to account for the largest market share and is estimated to register the fastest CAGR. This market dominance is due to the increasing number of cancer patients and subsequently increases cancer therapeutic strategies’ demand.

According to the National Cancer Institute, under the National Institute of Health (NIH), in 2020, approximately 1.8 million new cancer patients are diagnosed within the United States, and 606,520 patients among them are anticipated to meet fatal consequences.

According to NIH, the incidence rate of new cases is approximately 442.4 cases per 100,000 men and women annually, and the mortality rate is approx. 158.3 deaths per 100,000 men and women every year.